We used the high-throughput cellular viability PRISM assay to test the antiproliferative activity of BI-2493 in a larger cancer cell line panel than in our previous work (10), which allowed us to evaluate less frequently occurring genetic alterations such as KRAS WT amplifications. Here, KRAS is linked to cancer.